Looking ahead to possible US FDA approval of ALKS-5461 early next year, Alkermes PLC CEO Richard Pops hopes the product will lead to the evaluation of depression drug candidates via newer endpoints and bring the treatment of depression closer to precision medicine.
ALKS-5461 is a fixed-dose combination of the partial mu-opioid receptor agonist and kappa-opioid receptor antagonist buprenorphine with the mu-opioid receptor...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?